

19 August 2026

Treatment of Cancers in Secondary Care

I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of April 2026 to the end of June 2026, or the latest three-month period for which data is available. Please include data for all hospitals in the Health and Social Care Trust.

1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	48
1.2 Apalutamide (Erleada)	20
1.3 Cabazitaxel	<5
1.4 Darolutamide (Nubeqa)	61
1.5 Docetaxel	85
1.6 Enzalutamide (Xtandi)	152
1.7 Lutetium-177 PSMA-617 (Pluvicto)	0
1.7 Olaparib (Lynparza)	28
1.8 Relugolix (Orgovyx, Ryego)	0
1.9 Talazoparib (Talzenna)	0

2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	10
2.2 Olaparib (Lynparza) for prostate cancer	<5

19 August 2026

2.3 Talazoparib (Talzenna) for prostate cancer	0
2.4 Relugolix (Orgovyx) for prostate cancer	0

3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated in Cycle 1 or Dose 1
3.1 Abiraterone (Zytiga or generic abiraterone)	<5
3.2 Apalutamide (Erleada)	0
3.3 Cabazitaxel (Jevtana or generic cabazitaxel)	<5
3.4 Darolutamide (Nubeqa)	25
3.5 Enzalutamide (Xtandi)	19

4. How many patients were treated with the following combinations in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.

Name of medicine	<u>Total</u> Number patients treated	Number patients received <u>cycle 1 or dose 1</u>
4.1 Darolutamide (Nubeqa) + Docetaxel	<5	<5
4.2 Darolutamide (Nubeqa) monotherapy	58	23
4.3 Olaparib (Lynparza) + Abiraterone	0	0

5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated
5.1 Abiraterone	48
5.2 Enzalutamide	152

***This is data for all types of prostate cancer receiving these treatments.**

19 August 2026

6. How many patients were treated with darolutamide (Nubeqa) for the following indications and BlueTeq CDF codes between 1st April 2026 to the end of June 2026, or latest 3-month period for which data is available?

BlueTeq CDF code	BlueTeq CDF description (copied from CDF List)	Number of patients
DARO3	Darolutamide in combination with androgen deprivation therapy (ADT) for the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatment with docetaxel (TA1109)	Data Not Available

7. How many patients received the following products for Non-Small Cell Lung Cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Product	Number patients treated
7.1 Atezolizumab (Tecentriq)	<5
7.2 Cemiplimab (Libtayo)	0
7.3 Durvalumab (Imfinzi)	5
7.4 Nivolumab (Opdivo)	<5
7.5 Pembrolizumab (Keytruda)	20

8. How many patients received the following products for Non-Small Cell Lung Cancer as Neo-adjuvant or Adjuvant treatment in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

NSCLC as Neo-adjuvant or adjuvant therapy	Number patients treated
8.1 Atezolizumab	0
8.2 Durvalumab	<5
8.3 Nivolumab	<5
8.4 Pembrolizumab	<5
8.5 Durvalumab	Duplicate of Q8.2

19 August 2026

9. How many patients received the following combination or monotherapy for Non-Small Cell Lung Cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

NSCLC as Neo-adjuvant or adjuvant therapy	Number patients treated
9.1 Cemiplimab + Cisplatin or Carboplatin chemotherapy	0
9.2 Cemiplimab monotherapy	0

Some figures have been withheld and replaced with less than five (<5), this is due to the small geographical area of Northern Ireland and releasing the actual figure has the potential to make the patient identifiable.